BioWorld

April 26, 2004

Led By Aranesp, Enbrel Sales, Amgen's Q1 Earnings Strong

Exceeding consensus estimates, Amgen Inc.'s first-quarter results showed strong sales that analysts said leave the company poised for near-term growth. (BioWorld Today) Read More

Genzyme, Inamed Receive Approval For Dermal Filler

Mitochondrial Protein To Trigger Search For Parkinson's Therapies

Adventrx Moving Through Clinic After Raising Funds

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...